GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Myrexis (Myrexis) Cash, Cash Equivalents, Marketable Securities : $1.21 Mil (As of Jun. 2013)


View and export this data going back to 2013. Start your Free Trial

What is Myrexis Cash, Cash Equivalents, Marketable Securities?

Myrexis's quarterly cash, cash equivalents, marketable securities declined from Dec. 2012 ($81.31 Mil) to Mar. 2013 ($1.51 Mil) but then stayed the same from Mar. 2013 ($1.51 Mil) to Jun. 2013 ($1.21 Mil).

Myrexis's annual cash, cash equivalents, marketable securities declined from Jun. 2011 ($105.64 Mil) to Jun. 2012 ($88.38 Mil) and declined from Jun. 2012 ($88.38 Mil) to Jun. 2013 ($1.21 Mil).


Myrexis Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Myrexis's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Cash, Cash Equivalents, Marketable Securities Chart

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 169.10 138.88 105.64 88.38 1.21

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.38 84.34 81.31 1.51 1.21

Myrexis Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Myrexis  (OTCPK:MYRX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Myrexis Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Myrexis's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Myrexis (Myrexis) Business Description

Industry
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.
Executives
Xstelos Corp. 10 percent owner 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe director 1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper director 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman director, officer: Chairman, President and CEO 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle director 320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska director, officer: Chief Operating Officer 749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer director, officer: President and CEO C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden director, officer: President and CEO 320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie officer: Chief Operating Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines